The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | MITOPE: RSO-021, a novel PRX3 inhibitor, in mesothelioma or other pleural cancers
Dean Fennell, FRCP, PhD, University of Leicester, Leicester, UK, comments on the Phase I MITOPE trial (NCT05278975), evaluating the safety and maximum tolerated dose (MTD) of intra-pleural RSO-021 in patients with mesothelioma or other pleural cancers. RSO-021, a cyclic oligopeptide targeting mitochondrial PRX3, demonstrated signs of anti-tumor activity and manageable toxicity at 90 mg/week, with common side effects including fatigue, pyrexia, and elevated creatinine. The trial supports further Phase II studies of RSO-021 as a monotherapy and in combination with other therapies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Bristol Myers Squibb; RS Oncology (Inst)
Consulting or Advisory Role – Bristol-Myers Squibb; RS Oncology
Speakers’ Bureau – BMS; Boehringer Ingelheim
Research Funding – Astex Pharmaceuticals (Inst); Bayer (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Owkin (Inst); Roche UK (Inst); RS Oncology (Inst)
Travel, Accommodations, Expenses – Bristol-Myers Squibb; Janssen Oncology; RS Oncology
